Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0012655,
umls-concept:C0025153,
umls-concept:C0032150,
umls-concept:C0039298,
umls-concept:C0080103,
umls-concept:C0087111,
umls-concept:C0178602,
umls-concept:C0370231,
umls-concept:C0392756,
umls-concept:C0427728,
umls-concept:C0559546,
umls-concept:C0699870,
umls-concept:C0871261,
umls-concept:C1313904,
umls-concept:C1442989,
umls-concept:C1515655,
umls-concept:C1533691,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
pubmed:issue |
2
|
pubmed:dateCreated |
1991-9-26
|
pubmed:abstractText |
Fifty-three asymptomatic Tanzanian school children with 400-31,000 asexual Plasmodium falciparum parasites/microliter of blood were given standard, one-half, one-quarter, or one-eighth of the recommended mefloquine treatment dose of 25 mg base/kg body weight. Mefloquine and main metabolite concentrations were determined in 100 microliters of capillary blood using a high performance liquid chromatographic method. In the standard, one-half, and one-quarter dose groups, all children cleared the parasites within three days after treatment. Reappearance was noted in one of the children in the one-quarter dose group during 49-56 days of followup. Among the children given one-eighth of a dose, two had an RII response and four had an RI response with early recrudescence. All 24-hour in vitro micro-tests (n = 30) showed full susceptibility for mefloquine. Adverse gastrointestinal reactions were reported by eight children on the first day after treatment, four of whom had been given a standard dose. These children had higher mefloquine concentrations one day after treatment than the other children in this group (P less than 0.05). In the standard dose group (n = 13), the area under the curve of capillary whole blood concentrations of mefloquine versus time was 52.4-112.1 mumol/liter x days. The highest concentration on day 1 was 2.75-7.20 mumol/liter and the median terminal half-life was 17.4 days. The highest concentrations of the main metabolite were observed 1-2 weeks after treatment and the median half-life was 18.9 days. The concentrations in the other groups were approximately proportional to those in the standard dose group both for mefloquine and the metabolite.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0002-9637
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
254-62
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1877721-Adolescent,
pubmed-meshheading:1877721-Animals,
pubmed-meshheading:1877721-Child,
pubmed-meshheading:1877721-Chloroquine,
pubmed-meshheading:1877721-Drug Administration Schedule,
pubmed-meshheading:1877721-Humans,
pubmed-meshheading:1877721-Malaria,
pubmed-meshheading:1877721-Mefloquine,
pubmed-meshheading:1877721-Plasmodium falciparum,
pubmed-meshheading:1877721-Tanzania
|
pubmed:year |
1991
|
pubmed:articleTitle |
Standard and reduced doses of mefloquine for treatment of Plasmodium falciparum in Tanzania: whole blood concentrations in relation to adverse reactions, in vivo response, and in vitro susceptibility.
|
pubmed:affiliation |
Department of Infectious Diseases, Roslagstull Hospital, Karolinska Institute, Stockholm, Sweden.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|